Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence.

Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06511, USA.
Journal of Substance Abuse Treatment (Impact Factor: 3.14). 07/2007; 32(4):399-409. DOI: 10.1016/j.jsat.2006.10.005
Source: PubMed

ABSTRACT Clinicians treating human immunodeficiency virus (HIV)-infected patients with substance use disorders often face the challenge of managing patients' acute or chronic pain conditions while keeping in mind the potential dangers of prescription opiate dependence. In this clinical review, we critically appraise the existing data concerning barriers to appropriate treatment of pain among HIV-infected patients with substance use disorders. We then analyze published studies concerning the choice of pharmacological pain control regimens for acute and chronic pain conditions in HIV-infected patients, keeping in mind HIV-specific issues related to drug interactions and substance use disorders. We summarize this information in the form of flowcharts for physicians approaching HIV-infected patients who present with complaints of pain, providing evidence-based guidance for the structuring of pain management services and for addressing aberrant drug-taking behaviors.

Download full-text


Available from: Frederick Altice, Jan 09, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Este estudio toma como marco teórico el modelo de miedo-evitación del dolor. Su objetivo es determinar, en un grupo de personas en tratamiento por presentar un trastorno de dependencia, si quienes desarrollaron dolor crónico tras el período de abstinencia se diferencian de aquellos en los que el dolor no persistió en un conjunto de variables que, según el modelo de miedo-evitación, estarían implicadas en la cronificación: sensibilidad a la ansiedad, evitación experiencial, miedo al dolor, formas de afrontamiento, depresión, ansiedad y calidad de vida. Se contrastó también la existencia de diferencias en la presencia de patología dual, policonsumo, medicación y dosis de metadona. Se comparó un grupo con dolor crónico (n= 63) y otro sin dolor (n= 58). Los estadísticos MANOVA y c2 mostraron que el grupo con dolor había recibido el diagnóstico de patología dual con mayor frecuencia que quienes no tenían dolor, presentaban un policonsumo más elevado, les habían sido prescritas dosis mayores de metadona y más medicamentos. El grupo de dolor presentaba peor calidad de vida y puntuaciones significativamente más altas en sensibilidad a la ansiedad, evitación experiencial y depresión. No se encontraron diferencias significativas respecto a las formas de afrontamiento, miedo al dolor y ansiedad.
    Psicothema 12/2009; 21(Número 2). · 0.96 Impact Factor
  • Fertility and Sterility 09/2011; 96(3). DOI:10.1016/j.fertnstert.2011.07.714 · 4.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In Australia and New Zealand, in parallel with other developed countries, the number of patients prescribed opioids on a long-term basis has grown rapidly over the last decade. The burden of chronic pain is more widely recognised and there has been an increase in the use of opioids for both cancer and non-cancer indications. While the prevalence of illicit opioid use has remained relatively stable, the diversion and abuse of prescription opioids has escalated, as has the number of individuals receiving methadone or buprenorphine pharmacotherapy for opioid addiction. As a result, the proportion of opioid-tolerant patients requiring acute pain management has increased, often presenting clinicians with greater challenges than those faced when treating the opioid-naïve. Treatment aims include effective relief of acute pain, prevention of drug withdrawal, assistance with any related social, psychiatric and behavioural issues, and ensuring continuity of long-term care. Pharmacological approaches incorporate the continuation of usual medications (or equivalent), short-term use of sometimes much higher than average doses of additional opioid, and prescription of non-opioid and adjuvant drugs, aiming to improve pain relief and attenuate opioid tolerance and/or opioid-induced hyperalgesia. Discharge planning should commence at an early stage and may involve the use of a 'Reverse Pain Ladder' aiming to limit duration of additional opioid use. Legislative requirements may restrict which drugs can be prescribed at the time of hospital discharge. At all stages, there should be appropriate and regular consultation and liaison with the patient, other treating teams and specialist services.
    Anaesthesia and intensive care 09/2011; 39(5):804-23. · 1.47 Impact Factor